Working… Menu

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00688766
Recruitment Status : Terminated (Based on Independent Data Monitoring Committee (IDMC) recommendation.)
First Posted : June 3, 2008
Last Update Posted : December 11, 2012
MedImmune LLC
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009
Certification/Extension First Submitted : December 6, 2012